Literature DB >> 18088340

Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass.

S Selleng1, K Selleng, H-G Wollert, B Muellejans, T Lietz, T E Warkentin, A Greinacher.   

Abstract

BACKGROUND: The diagnosis of heparin-induced thrombocytopenia (HIT) is problematic in postcardiac surgery (CS) intensive care unit (ICU) patients, as there are multiple potential explanations for thrombocytopenia and the presence of anti-platelet factor 4/heparin antibodies is not highly specific for HIT. Two platelet count profiles for HIT - a 40% or greater fall in platelet count beginning on or after day 5 (pattern 1) and persisting thrombocytopenia (< 100 x 10(9) L(-1)) beyond day 7 (pattern 2) - have been described in post-CS patients. METHODS AND
RESULTS: We examined the platelet count profiles of 329 consecutive post-CS patients who required ICU treatment beyond 7 days. Although 70 patients (21.3%) developed thrombocytopenia (57.1% pattern 1, 42.9% pattern 2), the overall incidence of HIT was only 1.8% [6/329; 95% confidence interval (95% CI) 0.7-3.9%] in these ICU patients, with more HIT patients showing a pattern 2 than a pattern 1 platelet count decrease (four vs. two patients). Notably, pattern 2 patients with HIT also showed a new proportional fall of > 30% in platelet count between postoperative days 5 and 10. Among the remaining 2242 post-CS patients without a prolonged ICU stay, only three (0.1%; 95% CI 0.03-0.4%) developed symptomatic HIT (OR 0.07; 95% CI 0.01-0.3; P = 0.0002 vs. ICU patients), all presenting with pattern 1.
CONCLUSIONS: Among post-CS ICU patients, a postoperative platelet count fall between days 5 and 10 increases diagnostic specificity for HIT, irrespective of whether this platelet count fall occurs after postoperative platelet count recovery (pattern 1) or is superimposed upon persisting postoperative thrombocytopenia (pattern 2). A prospective study is required in order to validate the findings of this retrospective analysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18088340     DOI: 10.1111/j.1538-7836.2007.02870.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

Review 1.  Diagnosis and management of heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-13       Impact factor: 3.722

2.  Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study.

Authors:  Sixten Selleng; Kathleen Selleng; Sigrun Friesecke; Matthias Gründling; Sven-Olaf Kuhn; Ricarda Raschke; Olivia J Heidecke; Carsten Hinz; Gregor Hron; Theodore E Warkentin; Andreas Greinacher
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

3.  Consensus Report on Patient Blood Management in Cardiac Surgery by Turkish Society of Cardiovascular Surgery (TSCVS), Turkish Society of Cardiology (TSC), and Society of Cardio-Vascular-Thoracic Anaesthesia and Intensive Care (SCTAIC).

Authors:  Serkan Ertugay; Türkan Kudsioğlu; Taner Şen
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-10-23       Impact factor: 0.332

Review 4.  Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?

Authors:  Heleen M Oudemans-van Straaten; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-01-24       Impact factor: 9.097

5.  A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients.

Authors:  Scott T Benken; Nicholas Tillman; Suhuir Dajani; Aesha Shah; Toby Thomas
Journal:  J Cardiothorac Surg       Date:  2014-03-21       Impact factor: 1.637

6.  Heparin-induced thrombocytopenia following coronary artery bypass grafting: a diagnostic dilemma.

Authors:  Raju Khanal; Paras Karmacharya; Daniel A Forman
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-10-19

7.  Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity.

Authors:  Thi-Huong Nguyen; Nikolay Medvedev; Mihaela Delcea; Andreas Greinacher
Journal:  Nat Commun       Date:  2017-05-22       Impact factor: 14.919

8.  Thrombocytopenia and platelet course on hospital mortality in neurological intensive care unit: a retrospective observational study from large database.

Authors:  Dawei Zhou; Zhimin Li; Lei Wu; Guangzhi Shi; Jianxin Zhou
Journal:  BMC Neurol       Date:  2020-05-30       Impact factor: 2.474

9.  Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG).

Authors:  Kimberley Doucette; Christin B DeStefano; Natasha A Jain; Allan L Cruz; Vera Malkovska; Kelly Fitzpatrick
Journal:  Res Pract Thromb Haemost       Date:  2017-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.